Medical research firm announces MBO following significant investment

Epistem, a contract research company, announces that following investment by Foresight Group it has completed a management buy-out of Genedrive.

Epistem provides both pre-clinical and clinical research services across several specialist therapeutic areas, including oncology, gastro-intestinal (GI) diseases and toxicity and inflammatory diseases. Clients include several global pharmaceutical businesses, US Biodefence programmes and niche biotechnology companies.

Dr Catherine Booth, CEO, Epistem, commented: “We are delighted to partner with Foresight. Epistem has huge potential for growth and development. We have a clear list of initiatives for enhancing and expanding the business and are looking forward to delivering a more comprehensive suite of services to address our customers’ scientific needs. Foresight, complemented by Nick Ash, will provide us with significant financial and strategic support.”

Foresight’s investment, which includes an injection of growth capital, will support the management team’s clear plans for growth, enabling expansion of the service offering, including further investment in next generation sequencing and laser capture technologies to complement current services identifying and validating targets and biomarkers.

Dr Nick Ash, non-executive chairman, Epistem, added: “I am looking forward to working with Cath and the management team at Epistem to accelerate the growth of the business, and build a company that excels in customer service and provides an outstanding environment in which to work.”

The team also plan investments in GI disease models, developing both organoid and microbiota services, along with expansion into chronic disease models such as fibrosis. The business will also strengthen its sales and marketing activities across its international customer base.

Matthew Pomroy, investment manager, Foresight, commented: “Epistem is a prime example of the type of company Foresight likes to support, a differentiated and customer-focused business with market leading expertise. Cath’s dedication and long term involvement, combined with the new expertise from incoming chairman Dr Nick Ash, gives us confidence that we will see the business go from strength-to-strength.  We look forward to working with the team in the coming years.”